Accelera partner appointed to Oncolytics Biotech board  

by • November 6, 2017 • Feature, Feature Slider, Feature-HomeComments Off on Accelera partner appointed to Oncolytics Biotech board  221

Deborah Brown

Deborah Brown, managing partner of specialty consultancy firm Accelera Canada has been named to the board of directors of Oncolytics Biotech Inc. 

Oncolytics is developing Reolysin, an intravenously delivered immuno-oncolytic virus that is a potential treatment for a variety of tumour types.  

As managing partner of Accelera Canada, Brown is involved in helping emerging biopharma ventures in the United States and Europe with the development and implementation of Canadian market strategies. Oncolytics hopes to use her expertise in helping commercialize it cancer therapeutic. 

“Ms. Brown’s wealth of experience in new product launches and market expansion will lend valuable insights as we progress Reolysin toward commercialization,” said Dr. Matt Coffey, president, and CEO of Oncolytics Biotech. “In addition to successfully leading the launch of a blockbuster drug in a new therapeutic category, Ms. Brown has experience in regulatory affairs, research and development and business development, which will support our clinical development programs and our pursuit of research collaborations and commercialization partnerships.” 

Related content 

Oncolytics’ Reolysin gets fast track designation from FDA 

Brown held progressively senior roles at EMD Serono from 2000 to 2014, including executive vice-president of neuroimmunology for the company’s U.S. operations, and president and managing director of the company’s Canadian operations.  

In 2012, she was Chair of the National Pharmaceutical Organization (now Innovative Medicines Canada) and served on its board of directors from 2007 to 2014.  

Brown sits on the Boards of Life Sciences Ontario, the Strategic Executive Advisory Council for Canadian Cancer Trials Group, and her local SPCA. She holds an MBA from University of Western Ontario’s Ivey School of Business, a Hons B.Sc. from the University of Guelph and completed the Merck executive development program at the University of Hong Kong, INSEAD and Northwestern University’s Kellogg School of Management. 

Comments are closed.